Consider a speculative investment in QURE, a biotech company whose future depends on a favorable FDA decision regarding its Huntington's disease therapy. A positive regulatory outcome could cause the stock to surge, while a negative one would force a lengthy and costly new trial. Another high-risk opportunity is G, which is developing a catheter-based treatment to maintain weight loss after patients stop using GLP-1 drugs. The success of G hinges on positive clinical data releases expected over the next 12 months. Both investments are highly speculative and require positive catalysts from either regulators or clinical trials to succeed.

Unicure (QURE)

• Unicure is a Dutch biotech company developing an experimental gene therapy for Huntington's disease.
• The stock price soared over 300% in September after a three-year study showed its treatment slowed the progression of the disease by 75%.
  • The therapy is delivered directly into the brain.
  • The scientific community hailed the results as a "stunning breakthrough."
  • The treatment could be highly profitable, as similar gene therapies can cost over $2 million.
• However, the stock lost nearly all its gains on November 3rd after the FDA announced it would no longer accept the company's data for a Biologics License Application (BLA) submission.
  • The issue is that Unicure used "external controls" for its study, which the FDA now considers not robust enough compared to a placebo-controlled study.
  • This is a reversal of the FDA's previous stance from 2024, where it had indicated it would accept the external control method.
  • A new study could take years to complete, creating significant uncertainty.

Takeaways

• High-Risk, High-Reward: QURE is a highly speculative investment. Its future is almost entirely dependent on a regulatory outcome with the FDA.
• Potential Catalyst: A positive outcome could involve the FDA reversing its decision or working with Unicure to find a resolution without a multi-year new study. This would likely cause the stock price to increase significantly.
• Major Risk: The primary risk is that the FDA holds its ground, forcing the company into a long and expensive new trial, which would keep the stock price depressed for the foreseeable future. The speaker notes they have a small position, highlighting the speculative nature of this investment.

Fractal Health (G)

• Fractal Health has developed a catheter-based treatment for obesity.
• The treatment is designed to help patients maintain weight loss after they stop using GLP-1 drugs (like Ozempic or Wegovy), which is a common problem.
  • It works by using heat and water to resurface the lining of the duodenum (the first part of the small intestine), which helps reset the body's blood sugar regulation.
• Data published in September showed that patients who underwent the therapy continued to lose weight for three months after stopping GLP-1 drugs.
• The treatment has a massive potential market and an attractive cost.
  • The estimated cost is $5,000 to $10,000, which could be appealing to insurance providers.
  • If just 0.5% of obese individuals in the US used the therapy, it could generate over $1 billion in revenue, compared to Fractal's current market cap of just $100 million.

Takeaways

• High-Risk, High-Upside: G is presented as a stock with a "clear path to upside" but requires a "good dose of caution."
• Key Catalysts: The company's future success ("lives or dies") depends on upcoming data releases over the next 12 months.
  • Investors should watch for announcements of new data from larger and longer-term studies.
• Major Risk: The current positive data is based on a very small sample size (129 patients) and a short duration (3 months). If future, more comprehensive data does not confirm these early results, the investment thesis would likely fail. The speaker has a small position, indicating this is a speculative play on future clinical trial results.